Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease

Neuroscience

Volumn 267, Issue , 2014, Pages 114-121

  Carriere, C H ^a   Kang, N H ^a   Niles, L P ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Intrastriatal; Neuroprotection; Parkinson's disease; Rotenone; Valproic acid

Indexed keywords

DRINKING WATER; ROTENONE; TYROSINE 3 MONOOXYGENASE; VALPROIC ACID; INSECTICIDE; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL COUNT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; FORELIMB; MALE; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; BODY EQUILIBRIUM; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HEMISPHERIC DOMINANCE; METABOLISM; PATHOLOGY; SENSATION DISORDERS; SPRAGUE DAWLEY RAT; TIME; TOXICITY;

ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FUNCTIONAL LATERALITY; INSECTICIDES; MALE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; POSTURAL BALANCE; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SENSATION DISORDERS; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VALPROIC ACID;

EID: 84897084346     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.02.028     Document Type: Article

References (40)

1. Alam M., Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 2002, 136(1):317-324.
2. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of parkinson's disease. Neurobiol Dis 2009, 34(2):279-290.
3. Chen P.S., Peng G.S., Li G., Yang S., Wu X., Wang C.C., Wilson B., Lu R.B., Gean P.W., Chuang D.M., Hong J.S. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006, 11(12):1116-1125.
4. Chiu C.T., Wang Z., Hunsberger J.G., Chuang D.M. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 2013, 65(1):105-142.
5. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39(6):889-909.
6. D'Souza A., Onem E., Patel P., La Gamma E.F., Nankova B.B. Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation. Brain Res 2009, 1247:1-10.
7. Duarte E.P., Curcio M., Canzoniero L.M., Duarte C.B. Neuroprotection by GDNF in the ischemic brain. Growth Factors 2012, 30(4):242-257.
8. Fleming S.M., Delville Y., Schallert T. An intermittent, controlled-rate, slow progressive degeneration model of parkinson's disease: antiParkinson effects of sinemet and protective effects of methylphenidate. Behav Brain Res 2005, 156(2):201-213.
9. Frisch C., Husch K., Angenstein F., Kudin A., Kunz W., Elger C.E., Helmstaedter C. Dose-dependent memory effects and cerebral volume changes after in utero exposure to valproate in the rat. Epilepsia 2009, 50(6):1432-1441.
10. Gottlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
11. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of parkinson's disease in mice. Behav Brain Res 2005, 162(1):1-10.
12. Kidd S.K., Schneider J.S. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of parkinson's disease. Neuroscience 2011, 194:189-194.
13. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152(2):259-277.
14. Leng Y., Liang M.H., Ren M., Marinova Z., Leeds P., Chuang D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008, 28(10):2576-2588.
15. Lindholm P., Voutilainen M.H., Lauren J., Peranen J., et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
16. Lotharius J., Brundin P. Pathogenesis of parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002, 3(12):932-942.
17. Marinova Z., Ren M., Wendland J.R., Leng Y., Liang M.H., Yasuda S., Leeds P., Chuang D.M. Valproic acid induces functional heat-shock protein 70 via class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 2009, 111:976-987.
18. Mayhew T.M., Gundersen H.J. If you assume, you can make an ass out of u and me': a decade of the disector for stereological counting of particles in 3D space. J Anat 1996, 188(Pt 1):1-15.
19. Monti B., Gatta V., Piretti F., Raffaelli S.S., Virgili M., Contestabile A. Valproic acid is neuroprotective in the rotenone rat model of parkinson's disease: Involvement of alpha-synuclein. Neurotox Res 2010, 17(2):130-141.
20. Monti B., Polazzi E., Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2009, 2(1):95-109.
21. Mulcahy P., Walsh S., Paucard A., Rea K., Dowd E. Characterisation of a novel model of parkinson's disease by intra-striatal infusion of the pesticide rotenone. Neuroscience 2011, 181:234-242.
22. Niles L.P., Sathiyapalan A., Bahna S., Kang N.H., Pan Y. Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain. Int J Neuropsychopharmacol 2012, 15(9):1343-1350.
23. Norazit A., Meedeniya A.C., Nguyen M.N., Mackay-Sim A. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle. Brain Res 2010, 1360:119-129.
24. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press Inc, San Diego, California.
25. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and yeratogen. J Biol Chem 2001, 276:36734-36741.
26. Ren M., Leng Y., Jeong M., Leeds P.R., Chuang D.M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004, 89:1358-1367.
27. Ren X., Zhang T., Gong X., Hu G., Ding W., Wang X. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp Neurol 2013, 248:148-156.
28. Sands S.A., Guerra V., Morilak D.A. Changes in tyrosine hydroxylase mRNA expression in the rat locus coeruleus following acute or chronic treatment with valproic acid. Neuropsychopharmacol 2000, 22:27-35.
29. Saravanan K.S., Sindhu K.M., Mohanakumar K.P. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 2005, 1049(2):147-155.
30. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003, 179(1):9-16.
31. Sindhu K.M., Saravanan K.S., Mohanakumar K.P. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 2005, 1051(1-2):25-34.
32. Uversky V.N., Li J., Fink A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 2001, 500(3):105-108.
33. West M.J. Stereological methods for estimating the total number of neurons and synapses: Issues of precision and bias. Trends Neurosci 1999, 22(2):51-61.
34. Woodlee M.T., Kane J.R., Chang J., Cormack L.K., Schallert T. Enhanced function in the good forelimb of hemi-parkinson rats: compensatory adaptation for contralateral postural instability?. Exp Neurol 2008, 211(2):511-517.
35. Wu S.T., Ma Y., Zhang K., Zhang J.G. Effect of deep brain stimulation on substantia nigra neurons in a rat model of Parkinson's disease. Chin Med J (Engl) 2012, 125(22):4072-4075.
36. Voutilainen M.H., Back S., Peranen J., Lindholm P., et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp Neurol 2011, 228:99-108.
37. Voutilainen M.H., Back S., Porsti E., Toppinen L., et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 2009, 29:9651-9659.
38. Xiong N., Huang J., Zhang Z., Xiong J., Liu X., Jia M., Wang F., Chen C., Cao X., Liang Z., Sun S., Lin Z., Wang T. Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PLoS One 2009, 4(11):e7878.
39. Yang Y., Liu X., Long Y., et al. Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats. Int J Neuropsychopharmacol 2006, 9(1):51-61.
40. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001, 276(34):31674-31683.